Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
base editing
Biotech
Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor
The patient who had two grade 3 side effects after receiving VERVE-101 was asymptotic, and lab abnormalities resolved within days.
Max Bayer
Apr 2, 2024 7:00am
PKU in mice treated with base and prime editing
Nov 3, 2023 1:08pm
Beam lays off 20% of staff and culls CAR-T work to save cash
Oct 19, 2023 11:00am
Revvity rolls out base editing reagents for preclinical labs
Sep 28, 2023 1:57pm
Beam aims to dose first patient in sickle cell trial this year
Aug 8, 2023 4:10pm